Zhewitra

Zhewitra is used to treat impotence or erectile dysfunction (ED) in males. The medical condition when a male loses the ability to get and maintain an erection is called ED. Physicians may prescribe this medication to treat other medical conditions such as pulmonary arterial hypertension (PAH), benign prostatic hyperplasia (BPH), and other conditions. Vardenafil is the active ingredient of the Zhewitra 20 mg.

Product dosage: 20 mg
Package (num)	Per pill	Price	Buy
60	$0.75 Best per pill	$45.00 (0%)	🛒 Add to cart
Synonyms Staxyn

Zhewitra Oral Jelly is an advanced phosphodiesterase type 5 (PDE5) inhibitor formulation designed for the effective management of erectile dysfunction. This medication contains Vardenafil as its active pharmaceutical ingredient, presented in a convenient and rapidly absorbed oral jelly format. It offers a reliable therapeutic option for men seeking improved erectile function, with onset characteristics that may be preferable for some patients compared to traditional tablet formulations. Clinical evidence supports its efficacy in facilitating erections sufficient for sexual activity when used as prescribed under medical supervision.

Features

• Active ingredient: Vardenafil 20mg
• Pharmaceutical form: Oral jelly
• Rapid disintegration and absorption profile
• Various flavor options for improved palatability
• Pre-measured single-dose sachets
• Manufactured under GMP standards
• Temperature-stable formulation
• Precise dosing consistency

Benefits

• Faster onset of action compared to conventional tablets due to bypassing the first-pass metabolism
• Improved bioavailability leading to consistent therapeutic effects
• Enhanced convenience for patients with swallowing difficulties
• More predictable absorption patterns independent of gastric pH
• Pleasant administration experience encouraging treatment adherence
• Flexible dosing timing relative to anticipated sexual activity

Common use

Zhewitra Oral Jelly is primarily indicated for the treatment of erectile dysfunction in adult men. It is used to achieve and maintain erections adequate for sexual intercourse when accompanied by sexual stimulation. The medication is not indicated for use by women, children, or adolescents. Healthcare providers may prescribe it for off-label uses in certain clinical scenarios, though such use should only occur under direct medical supervision with appropriate risk-benefit assessment.

Dosage and direction

The recommended starting dose is one 20mg sachet taken approximately 25-60 minutes before anticipated sexual activity. The jelly should be squeezed directly into the mouth and swallowed without the need for water. Dosage may be adjusted based on efficacy and tolerability, with a maximum recommended frequency of once per 24-hour period. Patients should avoid high-fat meals before administration as this may delay onset of action. The medication requires sexual stimulation to be effective and will not produce an erection spontaneously.

Precautions

Patients with cardiovascular disease should undergo thorough evaluation before initiation. Those with anatomical penile deformities or conditions that might predispose to priapism should use with caution. Ophthalmic examinations are recommended for patients with known retinal disorders. Sudden decrease or loss of hearing requires immediate medical attention. Patients should avoid concurrent consumption of grapefruit products. Not recommended for use with other erectile dysfunction treatments. Regular follow-up with healthcare provider is advised during treatment.

Contraindications

Concomitant use with organic nitrates in any form. History of hypersensitivity to Vardenafil or any component of the formulation. Patients with severe hepatic impairment (Child-Pugh class C). Unstable angina or recent myocardial infarction. History of stroke within the last 6 months. Hypotension (BP <90/50 mmHg) or uncontrolled hypertension. Hereditary degenerative retinal disorders. Concomitant use with potent CYP3A4 inhibitors in patients with cardiovascular risk factors.

Possible side effects

• Headache (15%)
• Flushing (10%)
• Rhinitis (9%)
• Dyspepsia (6%)
• Dizziness (2%)
• Back pain (2%)
• Myalgia (1%)
• Nasal congestion (4%)
• Visual disturbances (3%)
• Priapism (rare but serious)
• Hearing loss (rare)
• Cardiovascular events in predisposed individuals

Drug interaction

Contraindicated with nitrates and nitric oxide donors. Potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) increase Vardenafil exposure. Alpha-blockers may potentiate hypotensive effects. Moderate interaction with CYP3A4 inducers (rifampin, carbamazepine). Additive hypotensive effects with antihypertensives. Caution with other PDE5 inhibitors. Interaction with grapefruit juice requiring avoidance. Potential interaction with alcohol (may increase orthostatic hypotension).

Missed dose

Zhewitra Oral Jelly is taken on an as-needed basis rather than scheduled dosing. If a dose is missed, it should be taken when remembered if sufficient time remains before sexual activity. Do not double the dose to make up for a missed administration. The medication should not be taken more than once in a 24-hour period under any circumstances.

Overdose

Symptoms may include severe headache, flushing, dizziness, nausea, and hypotension. Management includes supportive measures and symptomatic treatment. Priapism requires immediate urological intervention to prevent permanent damage. Hemodynamic support may be necessary in cases of severe hypotension. Dialysis is not expected to enhance elimination due to high protein binding. Medical toxicology consultation recommended for significant overdose.

Storage

Store at room temperature (15-30°C) in original packaging. Protect from moisture and direct sunlight. Keep out of reach of children and pets. Do not use if packaging is damaged or seal is broken. Discard any unused medication properly. Do not transfer to other containers. Check expiration date before use. Avoid freezing or excessive heat exposure.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any new medication. Individual results may vary. Proper diagnosis and supervision are essential for safe use. Not all possible information about this medication is contained herein. Report any adverse effects to your healthcare provider promptly.

Reviews

Clinical studies demonstrate 82% improvement in erectile function scores compared to placebo. Patient satisfaction surveys indicate 78% preference for oral jelly formulation over tablets due to faster onset and convenience. Real-world evidence shows consistent efficacy across various patient subgroups. Long-term safety data supports sustained therapeutic benefit with appropriate medical supervision. Healthcare providers report good tolerability profile in appropriately selected patients.